Smith & Nephew Plc SN. Directorate Change

  Smith & Nephew Plc (SN.) - Directorate Change

RNS Number : 0853Q
Smith & Nephew Plc
01 November 2012





                              Directorate Change

1 November 2012

Smith & Nephew plc (LSE: SN, NYSE: SNN), the global medical technology
business, today announces that Prof. Geneviève Berger has resigned as a
Non-Executive Director with effect from today.

Geneviève Berger, said

"I am sorry to be leaving Smith & Nephew at such an exciting time as the
business refocuses under Olivier's leadership. My decision reflects the
demands placed on my time from my wider commitments. I wish John, Olivier and
all at Smith & Nephew the very best for the future. "

Sir John Buchanan, Chairman of Smith & Nephew, commented:

"I would like to thank Geneviève for her contribution as a Non-Executive
Director and valuable member of our Ethics & Compliance Committee. I
understand her decision to concentrate her time on a more focused portfolio
and she leaves with the good wishes of us all."



Phil Cowdy
Tel: +44 (0) 20 7401 7646

Smith & Nephew


Charles Reynolds Tel:
+44 (0) 20 7401 7646

Smith & Nephew

Justine McIlroy / Andrew Mitchell Tel: +44
(0) 20 7404 5959

Brunswick - London

About Smith & Nephew

Smith & Nephew is a global medical technology business dedicated to helping
improve people's lives. With leadership positions in Orthopaedic
Reconstruction, Advanced Wound Management, Sports Medicine and Trauma, Smith &
Nephew has almost 11,000 employees and a presence in more than 90 countries.
Annual sales in 2011 were nearly $4.3 billion. Smith & Nephew is a member of
the FTSE100 (LSE: SN, NYSE: SNN).

Forward-looking Statements

This document may contain forward-looking statements that may or may not prove
accurate. For example, statements regarding expected revenue growth and
trading margins, market trends and our product pipeline are forward-looking
statements. Phrases such as "aim", "plan", "intend", "anticipate",
"well-placed", "believe", "estimate", "expect", "target", "consider" and
similar expressions are generally intended to identify forward-looking
statements. Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual results to
differ materially from what is expressed or implied by the statements. For
Smith & Nephew, these factors include: economic and financial conditions in
the markets we serve, especially those affecting health care providers, payors
and customers; price levels for established and innovative medical devices;
developments in medical technology; regulatory approvals, reimbursement
decisions or other government actions; product defects or recalls; litigation
relating to patent or other claims; legal compliance risks and related
investigative, remedial or enforcement actions; strategic actions, including
acquisitions and dispositions, our success in integrating acquired businesses,
and disruption that may result from changes we make in our business plans or
organisation to adapt to market developments; and numerous other matters that
affect us or our markets, including those of a political, economic, business
or competitive nature. Please refer to the documents that Smith & Nephew has
filed with the U.S. Securities and Exchange Commission under the U.S.
Securities Exchange Act of 1934, as amended, including Smith & Nephew's most
recent annual report on Form 20-F, for a discussion of certain of these

Any forward-looking statement is based on information available to Smith &
Nephew as of the date of the statement. All written or oral forward-looking
statements attributable to Smith & Nephew are qualified by this caution. Smith
& Nephew does not undertake any obligation to update or revise any
forward-looking statement to reflect any change in circumstances or in Smith &
Nephew's expectations.

                     This information is provided by RNS
           The company news service from the London Stock Exchange


BOABGBDBGDGBGDB -0- Nov/01/2012 11:02 GMT
Press spacebar to pause and continue. Press esc to stop.